Comparative Pharmacology
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus PYLARIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus PYLARIFY.
IODOHIPPURATE SODIUM I 131 vs PYLARIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
Gallium Ga 68 gozetotide is a radioactive diagnostic agent that binds to prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells. It allows for positron emission tomography (PET) imaging of PSMA-positive lesions.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
1 mg/kg IV bolus administered once.
None Documented
None Documented
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
Terminal elimination half-life of approximately 12.3 hours (range 8-18 hours), supporting once-daily dosing in clinical practice.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Renal (approximately 99% of administered dose as unchanged drug) and fecal (<1%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical